<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-787
Date of Submission: 2024-11-08

This report was submitted by a Patient from Banks, Johnson and King Medical Center concerning patient ANON-PX-8443. The subject is an adult other with a significant medical history including chronic kidney disease, type 2 diabetes, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 186mg, initiated on 2024-09-10 for Hypercholesterolemia and discontinued on 2024-10-30; Sertraline (SSRI) administered via the Topical route at a dosage of 373mg, initiated on 2024-09-10 for Major depressive disorder and discontinued on 2024-10-30.

On approximately 2024-09-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Anaphylaxis. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Ability toward choice guy. Else long hold around when always her. Effect adult single glass plan customer.</data>
report_id: ADR-2024-787
report_date: '2024-11-08'
patient_details:
  patient_id: ANON-PX-8443
  gender: Other
  relevant_history:
  - chronic kidney disease
  - type 2 diabetes
  - migraines
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 186mg
  route_of_administration: Subcutaneous
  start_date: '2024-09-10'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2024-10-30'
- drug_name: Sertraline
  dosage: 373mg
  route_of_administration: Topical
  start_date: '2024-09-10'
  indication_for_use: Major depressive disorder
  drug_class: SSRI
  end_date: '2024-10-30'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2024-09-29'
  severity: Mild
  outcome: Recovering
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2024-09-29'
  severity: Severe
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 6
reporting_facility: Banks, Johnson and King Medical Center
reporter_type: Patient
notes: Ability toward choice guy. Else long hold around when always her. Effect adult
  single glass plan customer.
